Literature DB >> 25483291

Effects of metformin on energy intake and satiety in obese children.

M A Adeyemo1, J R McDuffie, M Kozlosky, J Krakoff, K A Calis, S M Brady, J A Yanovski.   

Abstract

AIMS: To investigate the effects of metformin on appetite and energy intake in obese children with hyperinsulinaemia.
METHODS: We conducted a 6-month randomized, double-blind, placebo-controlled trial to evaluate the effects of metformin 1000 mg twice daily on body weight and energy balance in 100 obese children with hyperinsulinaemia aged 6-12 years. The children ate ad libitum from standardized food arrays on two separate occasions before and after 6 months of study medication. The first test meal was consumed after an overnight fast. The second was preceded by a pre-meal load. For each test meal, energy intake was recorded, and the children completed scales of hunger, fullness and desire to eat.
RESULTS: Data from the meal studies at baseline and after treatment with study medication were available for 84 children (metformin-treated, n = 45; placebo-treated, n = 39). Compared with placebo, metformin treatment elicited significant reductions from baseline in adjusted mean ± standard error of the mean energy intake after the pre-meal load (metformin: -104.7 ± 83.8 kcal vs. placebo: +144.2 ± 96.9 kcal; p = 0.034) independently of changes in body composition. Metformin also significantly decreased ratings of hunger (-1.5 ± 5.6 vs. +18.6 ± 6.3; p = 0.013) and increased ratings of fullness (+10.1 ± 6.2 vs. -12.8 ± 7.0; p = 0.01) after the pre-meal load.
CONCLUSIONS: These data suggest that decreased perceived hunger resulting in diminished food intake are among the mechanisms by which metformin treatment reduces body weight in overweight children with hyperinsulinaemia. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  child; energy intake; insulin resistance; metformin; obesity

Mesh:

Substances:

Year:  2015        PMID: 25483291      PMCID: PMC4357555          DOI: 10.1111/dom.12426

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  34 in total

1.  Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Authors:  A Maida; B J Lamont; X Cao; D J Drucker
Journal:  Diabetologia       Date:  2010-10-23       Impact factor: 10.122

2.  Gastrointestinal correlates of the development of hunger in man.

Authors:  C P Sepple; N W Read
Journal:  Appetite       Date:  1989-12       Impact factor: 3.868

3.  Effectiveness of metformin on weight loss in non-diabetic individuals with obesity.

Authors:  C Seifarth; B Schehler; H J Schneider
Journal:  Exp Clin Endocrinol Diabetes       Date:  2012-11-12       Impact factor: 2.949

4.  Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.

Authors:  Shubha Srinivasan; Geoffrey R Ambler; Louise A Baur; Sarah P Garnett; Mirijana Tepsa; Fabian Yap; Glenn M Ward; Christopher T Cowell
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

5.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version.

Authors:  Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

Review 6.  Biguanides and NIDDM.

Authors:  C J Bailey
Journal:  Diabetes Care       Date:  1992-06       Impact factor: 19.112

7.  Weight-reducing effect of diguanides in obese non-diabetic women.

Authors:  J F Munro; A C MacCuish; A Marshall; E M Wilson; L J Duncan
Journal:  Br Med J       Date:  1969-04-05

8.  Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.

Authors:  Nobuyuki Yasuda; Takashi Inoue; Tadashi Nagakura; Kazuto Yamazaki; Kazunobu Kira; Takao Saeki; Isao Tanaka
Journal:  J Pharmacol Exp Ther       Date:  2004-03-23       Impact factor: 4.030

9.  Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.

Authors:  Tongzhi Wu; Jing Ma; Michelle J Bound; Helen Checklin; Carolyn F Deacon; Karen L Jones; Michael Horowitz; Christopher K Rayner
Journal:  Diabetes       Date:  2014-03-19       Impact factor: 9.461

Review 10.  Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

View more
  13 in total

Review 1.  Metabolic syndrome in children and adolescents.

Authors:  Dania Al-Hamad; Vandana Raman
Journal:  Transl Pediatr       Date:  2017-10

Review 2.  Drug interventions for the treatment of obesity in children and adolescents.

Authors:  Emma Mead; Greg Atkinson; Bernd Richter; Maria-Inti Metzendorf; Louise Baur; Nicholas Finer; Eva Corpeleijn; Claire O'Malley; Louisa J Ells
Journal:  Cochrane Database Syst Rev       Date:  2016-11-29

3.  Metformin Treatment in Old Rats and Effects on Mitochondrial Integrity.

Authors:  Allen Herbst; Austin Hoang; Chiye Kim; Judd M Aiken; Debbie McKenzie; Deena S Goldwater; Jonathan Wanagat
Journal:  Rejuvenation Res       Date:  2021-12       Impact factor: 4.663

Review 4.  Metformin: A Hopeful Promise in Aging Research.

Authors:  Marta G Novelle; Ahmed Ali; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

5.  Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.

Authors:  Dennis M Styne; Silva A Arslanian; Ellen L Connor; Ismaa Sadaf Farooqi; M Hassan Murad; Janet H Silverstein; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

6.  Retrospective Evaluation of Metformin and/or Metformin Plus a New Polysaccharide Complex in Treating Severe Hyperinsulinism and Insulin Resistance in Obese Children and Adolescents with Metabolic Syndrome.

Authors:  Stefano Stagi; Franco Ricci; Martina Bianconi; Maria Amina Sammarco; Giovanna Municchi; Sonia Toni; Lorenzo Lenzi; Alberto Verrotti; Maurizio de Martino
Journal:  Nutrients       Date:  2017-05-20       Impact factor: 5.717

7.  The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production.

Authors:  Hongying An; Yu Wang; Caolitao Qin; Mingsong Li; Akhil Maheshwari; Ling He
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

8.  Effect of Metformin on Short-Term High-Fat Diet-Induced Weight Gain and Anxiety-Like Behavior and the Gut Microbiota.

Authors:  Shuqin Ji; Lingwei Wang; Lei Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-18       Impact factor: 5.555

Review 9.  Metformin: a review of its potential indications.

Authors:  Yi-Wei Wang; Si-Jia He; Xiao Feng; Jin Cheng; Yun-Tao Luo; Ling Tian; Qian Huang
Journal:  Drug Des Devel Ther       Date:  2017-08-22       Impact factor: 4.162

10.  Insulin Resistance and Hunger in Childhood Obesity: A Patient and Physician's Perspective.

Authors:  Wendy Scinta; Harold Bayes; Nicole Smith
Journal:  Adv Ther       Date:  2017-09-07       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.